Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director · Pres. & Chief Exec. Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,064 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 8,165 · Balance 29,644 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. Row 2 · 2026-10-05 · Sale · Disposed 8,580 · Balance 21,064 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold Descendants 2020 Trust | 8,038 |
Reported balance
After 2026-10-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-05 · Sale · Disposed 3,198 · Balance 8,038 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. |
| Common StockSEC Table I · non-derivative | IndirectBy Derek Maetzold 2020 Irrevocable Trust | 6,832 |
Reported balance
After 2026-10-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-05 · Sale · Disposed 2,718 · Balance 6,832 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2028-05-09 | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-10-05 · Exercise / conversion · Disposed 8,165 · Balance 0 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F13: The shares subject to the option are fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,256 F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 11,256 F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 11,256 F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 11,256 F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 6 | 11,963 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 11,963 F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 7 | 27,862 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 27,862 F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 8 | 40,935 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 40,935 F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectDJM Grantor Retained Annuity Trust No. 9 | 23,216 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 23,216 F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.
F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.
F13: The shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2024 Filed Jun 5, 2024 21:23 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,192 | $23.39 | $27,883.26 |
DisclosureSEC source: 0001447362-24-000102 · wk-form4_1717622615.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 71,399 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.960 to $23.940, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:23 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,192 | $23.39 | $27,883.26 |
DisclosureSEC source: 0001447362-24-000102 · wk-form4_1717622615.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 82,502 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.960 to $23.940, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:23 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,328 | $23.39 | $54,456.58 |
DisclosureSEC source: 0001447362-24-000102 · wk-form4_1717622615.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,933 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.960 to $23.940, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 46 | $24.95 | $1,147.65 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 14 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 8,911 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F9 · price: This transaction was executed in multiple trades at prices ranging from $24.92 to $25.00, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 46 | $24.95 | $1,147.65 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 8,911 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F9 · price: This transaction was executed in multiple trades at prices ranging from $24.92 to $25.00, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 46 | $24.95 | $1,147.65 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 8,911 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F9 · price: This transaction was executed in multiple trades at prices ranging from $24.92 to $25.00, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 46 | $24.95 | $1,147.65 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 8,913 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F9 · price: This transaction was executed in multiple trades at prices ranging from $24.92 to $25.00, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 145 | $24.95 | $3,617.61 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 10 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 72,591 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F9 · price: This transaction was executed in multiple trades at prices ranging from $24.92 to $25.00, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 145 | $24.95 | $3,617.61 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 83,694 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F9 · price: This transaction was executed in multiple trades at prices ranging from $24.92 to $25.00, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 283 | $24.95 | $7,060.57 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,261 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F9 · price: This transaction was executed in multiple trades at prices ranging from $24.92 to $25.00, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 340 | $24.17 | $8,219.16 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 8,957 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.88 to $24.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 340 | $24.17 | $8,219.16 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 8,957 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.88 to $24.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 340 | $24.17 | $8,219.16 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 8,957 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.88 to $24.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 340 | $24.17 | $8,219.16 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 8,959 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.88 to $24.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,067 | $24.17 | $25,793.66 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 72,736 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.88 to $24.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,067 | $24.17 | $25,793.66 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 83,839 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.88 to $24.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,085 | $24.17 | $50,402.79 |
DisclosureSEC source: 0001447362-24-000070 · wk-form4_1715890832.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,544 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.88 to $24.51, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:47 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 386 | $24.72 | $9,541.92 |
DisclosureSEC source: 0001447362-24-000062 · wk-form4_1715201228.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 9,297 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.58 to $25.04, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:47 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 386 | $24.72 | $9,541.92 |
DisclosureSEC source: 0001447362-24-000062 · wk-form4_1715201228.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 9,297 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.58 to $25.04, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:47 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 386 | $24.72 | $9,541.92 |
DisclosureSEC source: 0001447362-24-000062 · wk-form4_1715201228.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 9,297 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.58 to $25.04, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:47 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 386 | $24.72 | $9,541.92 |
DisclosureSEC source: 0001447362-24-000062 · wk-form4_1715201228.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 9,299 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.58 to $25.04, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:47 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,212 | $24.72 | $29,960.64 |
DisclosureSEC source: 0001447362-24-000062 · wk-form4_1715201228.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 73,803 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.58 to $25.04, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:47 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,212 | $24.72 | $29,960.64 |
DisclosureSEC source: 0001447362-24-000062 · wk-form4_1715201228.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 84,906 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.58 to $25.04, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:47 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,368 | $24.72 | $58,536.96 |
DisclosureSEC source: 0001447362-24-000062 · wk-form4_1715201228.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,629 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.58 to $25.04, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:54 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 69 | $20.11 | $1,387.52 |
DisclosureSEC source: 0001447362-24-000052 · wk-form4_1714078450.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 9,683 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.010 to $20.185, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:54 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 69 | $20.11 | $1,387.52 |
DisclosureSEC source: 0001447362-24-000052 · wk-form4_1714078450.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 9,683 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.010 to $20.185, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:54 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 69 | $20.11 | $1,387.52 |
DisclosureSEC source: 0001447362-24-000052 · wk-form4_1714078450.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 9,683 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.010 to $20.185, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:54 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 68 | $20.11 | $1,367.41 |
DisclosureSEC source: 0001447362-24-000052 · wk-form4_1714078450.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 9,685 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.010 to $20.185, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:54 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 215 | $20.11 | $4,323.44 |
DisclosureSEC source: 0001447362-24-000052 · wk-form4_1714078450.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 75,015 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.010 to $20.185, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:54 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 215 | $20.11 | $4,323.44 |
DisclosureSEC source: 0001447362-24-000052 · wk-form4_1714078450.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 86,118 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.010 to $20.185, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:54 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 421 | $20.11 | $8,465.89 |
DisclosureSEC source: 0001447362-24-000052 · wk-form4_1714078450.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,997 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.010 to $20.185, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 20:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 317 | $20.35 | $6,450.95 |
DisclosureSEC source: 0001447362-24-000050 · wk-form4_1713300400.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 9,752 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.05 to $20.72, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 20:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 317 | $20.35 | $6,450.95 |
DisclosureSEC source: 0001447362-24-000050 · wk-form4_1713300400.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 9,752 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.05 to $20.72, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 20:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 317 | $20.35 | $6,450.95 |
DisclosureSEC source: 0001447362-24-000050 · wk-form4_1713300400.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 9,752 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.05 to $20.72, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 20:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 318 | $20.35 | $6,471.30 |
DisclosureSEC source: 0001447362-24-000050 · wk-form4_1713300400.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 9,753 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.05 to $20.72, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 20:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 997 | $20.35 | $20,288.95 |
DisclosureSEC source: 0001447362-24-000050 · wk-form4_1713300400.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 75,230 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.05 to $20.72, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 20:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 997 | $20.35 | $20,288.95 |
DisclosureSEC source: 0001447362-24-000050 · wk-form4_1713300400.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 86,333 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.05 to $20.72, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 20:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,947 | $20.35 | $39,621.45 |
DisclosureSEC source: 0001447362-24-000050 · wk-form4_1713300400.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,418 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.05 to $20.72, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:37 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 386 | $21.70 | $8,376.20 |
DisclosureSEC source: 0001447362-24-000035 · wk-form4_1712349465.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 10,069 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.28 to $22.15, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:37 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 386 | $21.70 | $8,376.20 |
DisclosureSEC source: 0001447362-24-000035 · wk-form4_1712349465.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 10,069 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.28 to $22.15, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:37 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 386 | $21.70 | $8,376.20 |
DisclosureSEC source: 0001447362-24-000035 · wk-form4_1712349465.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 10,069 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.28 to $22.15, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:37 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 386 | $21.70 | $8,376.20 |
DisclosureSEC source: 0001447362-24-000035 · wk-form4_1712349465.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 10,071 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.28 to $22.15, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:37 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,212 | $21.70 | $26,300.40 |
DisclosureSEC source: 0001447362-24-000035 · wk-form4_1712349465.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 76,227 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.28 to $22.15, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:37 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,212 | $21.70 | $26,300.40 |
DisclosureSEC source: 0001447362-24-000035 · wk-form4_1712349465.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 87,330 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.28 to $22.15, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:37 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,368 | $21.70 | $51,385.60 |
DisclosureSEC source: 0001447362-24-000035 · wk-form4_1712349465.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,365 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.28 to $22.15, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 21:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 12 | $20.70 | $248.40 |
DisclosureSEC source: 0001447362-24-000031 · wk-form4_1711142198.xml · nonDerivative · entry 14 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 10,455 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 21:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 12 | $20.70 | $248.40 |
DisclosureSEC source: 0001447362-24-000031 · wk-form4_1711142198.xml · nonDerivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 10,455 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 21:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 12 | $20.70 | $248.40 |
DisclosureSEC source: 0001447362-24-000031 · wk-form4_1711142198.xml · nonDerivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 10,455 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 21:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 11 | $20.70 | $227.70 |
DisclosureSEC source: 0001447362-24-000031 · wk-form4_1711142198.xml · nonDerivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 10,457 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 21:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 37 | $20.70 | $765.90 |
DisclosureSEC source: 0001447362-24-000031 · wk-form4_1711142198.xml · nonDerivative · entry 10 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 77,439 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on December 5, 2023. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.